Evidence map›Paper›PMID 29109096›Full record

ReviewCancer genomics & proteomics

DHPLC Elution Patterns of

Robert L Copeland, Desta Beyene, Victor Apprey, Mohammad R Daremipouran, Tammey J Naab, Olakunle O Kassim, Yasmine M Kanaan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. The Association of a Novel IdentifiedCancer genomics & proteomics
    Article
  3. The Association Between the GeneticCancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Robert L CopelandDepartment of Pharmacology, Howard University, Washington, DC, U.S.A.
Desta BeyeneCancer Center, Howard University, Washington, DC, U.S.A.
Victor AppreyDepartment of Community and Family Medicine, Howard University, Washington, DC, U.S.A.
Mohammad R DaremipouranCancer Center, Howard University, Washington, DC, U.S.A.
Tammey J NaabDepartment of Pathology, Howard University, Washington, DC, U.S.A.
Olakunle O KassimDepartment of Microbiology, Howard University, Washington, DC, U.S.A.
Yasmine M KanaanCancer Center, Howard University, Washington, DC, U.S.A. ymkanaan@howard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimDenaturing high-performance liquid chromatography (DHPLC) is a technique that is used to detect mutations. The aim of the present study was to determine whether DHPLC elution patterns of vitamin D receptor (VDR) gene PCR products can serve as indicators of susceptibility to prostate cancer (PCa) risk. MATERIALS AND

methodsDNA samples of PCa cases and controls were screened for mutations and/or polymorphisms in coding exons of VDR gene using DHPLC analysis. Logistic regression, phi-coefficient (ϕ), and Backward Wald models were used to analyze the data.

resultsSimilar elution patterns of exons 1, 6, 7 and 9 along with higher prevalence of heteroduplex DNA were observed in PCa samples than in controls. Exons 4 and 8 had highly significant protective effects (p<0.05). Whereas, exons 5, 7, and 9 were perfectly positively correlated with PCa risk (ϕ=1), thus presenting candidate exons significantly associated with susceptibility to PCa.

conclusionDHPLC elution patterns of the selected exons could be useful to predict susceptibility to develop PCa.

Indexed as

AdultBlack or African AmericanChromatography, High Pressure LiquidHumansMalePolymerase Chain ReactionProstatic NeoplasmsReceptors, CalcitriolReceptors, CalcitriolVDR protein, humanAfrican American menProstate cancervitamin Dvitamin D receptor gene

Identifiers

PMID29109096
PMCPMC6070329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.